Delta Sleep-Inducing Peptide (DSIP)
PeptideThe divergence is explained by community polarization: a subset reports profound sleep improvements (verified by wearables), while clinical evidence rests on small, methodologically limited studies from the 1980s that were never replicated. Additionally, DSIP is a peptide with high individual variability (estimated non-responder rate 30–40%), which skews community ratings upward as responders disproportionately report their experiences. The absence of pharmaceutical development and modern RCTs keeps the medical score low despite basic research demonstrating plausible mechanisms.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
DSIP is an endogenous nonapeptide that modulates delta-wave sleep, the HPA axis and the opioid system, with small historical RCTs from the 1980s showing modest sleep improvements. The community uses 100–300 mcg subcutaneously before bedtime, observing a strict U-shaped dose-response curve. Modern clinical trials are completely absent, and DSIP holds no drug approval (FDA compounding exclusion, WADA-banned S2). Key risks include paradoxical insomnia from overdosing, tolerance development and immunogenicity from impure preparations.
Description
Endogenous nonapeptide that modulates deep (delta-wave) sleep, the HPA axis and the endogenous opioid system; explored experimentally for insomnia and withdrawal syndromes.
What is DSIP? Delta Sleep-Inducing Peptide (DSIP) is a linear, endogenous neuropeptide comprising nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), first isolated in 1974 by Schoenenberger and Monnier in Basel from the venous blood of sleeping rabbits. Intracerebroventricular infusion into awake animals induced characteristic delta and spindle EEG patterns without the respiratory depression or REM suppression typical of benzodiazepines. Research History During the 1970s–1980s, DSIP was extensively studied in animal models and small human trials focusing on sleep, pain, the HPA axis and withdrawal syndromes. An open-label study in 107 hospitalized patients showed rapid alleviation of severe withdrawal symptoms in 97% of opiate-dependent and 87% of alcohol-dependent subjects. Small double-blind RCTs in chronic insomniacs found modest improvements in sleep efficiency and latency, while other trials reported only limited or inconsistent benefits. Despite promising early results, clinical development stalled in the 1990s due to inconsistent replication, a pronounced U-shaped dose-response curve, an extremely short plasma half-life (~7–8 min in humans) and lack of patentability. Current Status Today DSIP has re-emerged as a research peptide within biohacking and longevity communities, where it is used subcutaneously for sleep optimization, stress reduction and recovery. The FDA has placed DSIP on its compounding exclusion list, warning of immunogenicity risks from repeated injection of impure preparations. In sports, DSIP is banned as a doping substance (WADA S2). Modern, large-scale RCTs are completely absent.
Legal Status (DE)
No drug approval in Germany. Sold as a research peptide in a regulatory grey area; if marketed with therapeutic claims, classified as an unapproved medicinal product under the German Medicines Act. Listed on the WADA Prohibited List (Category S2, Peptide Hormones) – acquisition, possession and use in organized sport is illegal under the German Anti-Doping Act.
Mechanism of Action
DSIP acts as a pleiotropic neuromodulator without an identified specific receptor, triggering cascading reactions across multiple neurotransmitter systems whose effects persist for hours to days despite a plasma half-life of only 7–8 minutes ("hit-and-run" paradox). 1. GABA potentiation: DSIP crosses the blood-brain barrier and enhances GABA-activated ionic currents in hippocampal and cerebellar neurons, creating the neuro-inhibitory environment required for transition into delta-wave sleep [s13]. 2. NMDA blockade: Simultaneously, DSIP inhibits NMDA receptor-mediated potentiation in the cortex, dampening excitatory overstimulation [s13]. 3. Endogenous opioid release: At nanomolar concentrations, DSIP triggers calcium-dependent influx into medullary synaptosomes and prompts Met-enkephalin release, explaining both its analgesic properties and historical success in withdrawal syndromes [s10][s9]. 4. HPA axis dampening: Endogenous DSIP exhibits circadian rhythmicity (plasma peak ~15:00) and attenuates excessive cortisol spikes during HPA hyperactivity [s12]. 5. Melatonin stimulation: DSIP modulates alpha-1-adrenergic receptors in the pineal gland and stimulates N-acetyltransferase, the rate-limiting enzyme of melatonin synthesis [s4]. 6. U-shaped dose-response curve: Both sub-therapeutic and supra-therapeutic doses are ineffective or counterproductive, partially explaining inconsistent study outcomes [s1][s2].
Dosing
Schlafoptimierung (Community-Protokoll)
- Dose
- 100–300 mcg subcutaneous; start at 50–100 mcg
- Frequency
- 3–5× pro Woche
- Route
- subcutaneous
- Duration
- 4–8 Wochen on / 4 Wochen off
- Timing
- 30–60 minutes before bedtime
- With food
- optional
Stressreduktion (intranasal, Community)
- Dose
- 50–150 mcg intranasal
- Frequency
- 2–3× pro Woche
- Route
- intranasal
- Duration
- Intermittierend
- Timing
- Evening
- With food
- optional
Klinische Schlafforschung (historisch, i.v.)
- Dose
- 25 nmol/kg i.v. (approx. 1.5–2.5 mg)
- Frequency
- 1× täglich
- Route
- intravenous
- Duration
- Kurzzeit (3–5 Nächte)
- Timing
- Evening before bedtime, under clinical supervision
- With food
- optional
Substanzentzug (historisch klinisch)
- Dose
- 25 nmol/kg i.v.
- Frequency
- 1–2× täglich nach Bedarf
- Route
- intravenous
- Duration
- Während akuter Entzugsphase
- Timing
- At onset of withdrawal symptoms
- With food
- optional
No officially validated upper limit. Clinical trials administered up to 4 mg i.v. without acute organ toxicity. Community practice: single doses >500 mcg s.c. are considered the critical threshold (U-curve reversal, paradoxical insomnia).
General notes DSIP follows a strict U-shaped dose-response curve – increasing the dose when lacking efficacy is often counterproductive. Oral administration is ineffective due to enzymatic degradation in the gastrointestinal tract. The subcutaneous route has significantly lower bioavailability than the intravenous administration used in historical studies. Sleep optimization (community protocol, subcutaneous) Dose: 100–300 mcg. Frequency: 3–5× per week. Timing: 30–60 minutes before bedtime. Duration: 4–8 weeks on, then 4 weeks off. Start at 50–100 mcg, increase only in 25–50 mcg increments. Stress reduction (intranasal) Dose: 50–150 mcg. Frequency: 2–3× per week in the evening. Intranasal application partially bypasses first-pass metabolism, though bioavailability is variable. Important notes Cyclic use is essential to prevent tolerance and tachyphylaxis. No combination with benzodiazepines, Z-drugs, opiates or alcohol without medical supervision – additive CNS depression possible. If paradoxical insomnia or brain fog occurs, reduce the dose rather than increasing it.
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Lethargie / Folgetag-Müdigkeit (Brain Fog) Exogenous induction of delta waves can disrupt circadian rhythm. When the U-curve optimum is exceeded, neurochemical cascades persist into the morning, causing intense sleep hangover with cognitive impairment. | häufig | leicht |
| Kopfschmerzen Documented as a primary adverse effect in clinical RCTs of the 1980s. Likely attributable to changes in cerebral blood flow or mild vasoconstrictive properties via HPA axis modulation. | gelegentlich | leicht |
| Übelkeit / gastrointestinale Beschwerden Non-specific response to parenteral peptide administration. DSIP-like material and enkephalin receptors have been identified in the GI tract; systemic flooding can trigger mild nausea. | gelegentlich | leicht |
| Lebhafte Träume / Albträume DSIP-induced changes in sleep architecture (deep sleep and REM distribution) can lead to more intense dreaming. Reported by a subset of community users. | gelegentlich | leicht |
| Toleranz / Rebound-Insomnie Some users report diminishing efficacy and worsened sleep following discontinuation after prolonged use. Controlled data are lacking; based on anecdotal community reports. | gelegentlich | moderat |
| Immunogenität / Anaphylaxie-Risiko The FDA explicitly warns that injected, unsupervised peptides can be recognized as antigens by the immune system. Repeated injection of impure research chemical preparations carries a theoretical risk of severe autoimmune cascades or anaphylactic shock. | theoretisch | schwer |
| Paradoxe Insomnie / verschlechterter Schlaf In approximately 10–20% of users, DSIP transiently produces the opposite effect — increased alertness and fragmented sleep. Likely due to exceeding the U-curve optimum or individual sensitivity. | gelegentlich | moderat |
| Hormonelle Dysregulation (HPA-Achse) DSIP demonstrably modulates ACTH and cortisol secretion, as well as potentially the LH and GH axes. Chronic, uncontrolled administration could long-term desensitize the endocrine feedback system. | theoretisch | moderat |
| Schwindel / Benommenheit Mentioned in isolated clinical and anecdotal reports. Likely attributable to rapid central nervous modulation of GABA and glutamate currents, transiently affecting vestibular balance. | selten | leicht |
Contraindications
No toxicological data on teratogenicity or transfer into breast milk. As a neuroendocrine peptide with effects on the HPA axis and fetal development, it should be considered contraindicated.
DSIP actively interacts with opioid receptors. Uncontrolled co-administration during active intoxication carries risk of paradoxical respiratory depression, masked overdose, or fulminant neurological dysfunction.
Based on explicit FDA warnings regarding immunogenicity of gray-market DSIP preparations, pre-existing autoimmune conditions carry a massively increased risk of severe immunological cascades (flares).
DSIP deepens sleep and modulates brainstem networks. In untreated sleep apnea, respiratory events may worsen or arousal responses may be attenuated.
Sleep and the HPA axis are closely linked to mood and suicide risk. Experimental manipulation via DSIP without psychiatric supervision is hazardous in severe depression or bipolar disorder.
DSIP significantly alters macroscopic cerebral EEG activity (induction of spindles and delta waves). In unstable neurological conditions, seizure thresholds could potentially be shifted.
Animal studies demonstrate effects on heart rate and blood pressure. In unstable cardiovascular conditions, DSIP-induced autonomic fluctuations may be problematic.
Interactions
Synergistic
Approximately 80% of physiological GH secretion occurs during deepest NREM sleep. DSIP enforces and stabilizes delta sleep architecture, thereby creating the optimal endocrine window for GH secretagogues. Practitioners estimate a 20–40% potentiation of effect. Typical timing: DSIP (100–200 mcg) + ipamorelin (200–300 mcg) administered simultaneously 30–60 min before bedtime.
Selank inhibits enzymatic degradation of enkephalins, while DSIP triggers their release. Closed feedback loop: DSIP supplies the transmitter, Selank extends its half-life. Result: calm, stress-free sleep induction. Clinics offer this as a blend (e.g., 2 mg DSIP / 10 mg Selank).
DSIP modulates alpha-1-adrenergic receptors in the pineal gland and stimulates N-acetyltransferase (key enzyme of melatonin synthesis). Exogenous melatonin administered concurrently with DSIP may accelerate circadian synchronization and deliver an unambiguous sleep signal.
Epitalon acts deeply on pineal gland function and restores natural melatonin production independently of age. In longevity protocols, Epitalon repairs circadian rhythm long-term, while DSIP acutely provides the neuronal architecture for deep sleep. Strongly complementary synergy.
BPC-157 promotes systemic tissue healing and modulates the gut-brain axis (reduction of neuroinflammation). Practitioners combine BPC-157 (cellular repair) with DSIP (sleep environment) for maximal holistic nervous system recovery following chronic stress or trauma.
Caution
Both substance classes inhibit the CNS via GABA. DSIP directly potentiates GABA-activated ion currents at the neuronal level. Combination provokes uncontrollable synergistic CNS depression with risk of deep sedation, paradoxical respiratory depression, and extreme next-day lethargy. Medical supervision is mandatory.
DSIP acts as a potent modulator of the endogenous opioid system (inducing Met-enkephalin release) and competitively binds to mu- and delta-opioid receptors. Co-administration with active opiates unpredictably alters analgesia, may prematurely trigger withdrawal symptoms, or mask dangerous overdose.
DSIP has been used successfully to manage alcohol withdrawal. However, administration during acute alcohol intoxication is high-risk: receptor competition masks the severity of intoxication and leads to unpredictable neurological dysfunction.
DSIP is a key player in HPA axis regulation. Studies using the dexamethasone suppression test demonstrate abnormal cortisol/DSIP responses. Co-administration with synthetic corticosteroids may disrupt the endocrine feedback system and abolish the stress-regulating effect of DSIP.
DSIP actively blocks NMDA-activated potentiation in cortical neurons. Concurrent administration of other NMDA antagonists (high-dose magnesium threonate, ketamine) may cause excessive suppression of excitatory glutamate signaling pathways, resulting in pronounced cognitive sluggishness the following morning.
DSIP interacts with serotonergic systems. SSRIs/SNRIs alter serotonin levels and sleep architecture. The combination could have unpredictable effects on mood, REM sleep, and the HPA axis; specialist supervision is advisable.
Community Evidence
Top reported benefits
- Significantly deeper sleep with more delta and REM phases (wearable-verified, +30–40 min)
- Faster sleep onset (~30 min after s.c. injection)
- Vivid, lucid dreams and improved dream recall
- More refreshed awakening without hangover effect (unlike melatonin)
- Improved post-workout recovery (subjectively less muscle soreness)
- Stress reduction and general evening calmness
- Increased morning libido (occasionally reported)
Top reported issues
- High non-responder rate (estimated 30–40% report no noticeable effect)
- Paradoxical insomnia and restlessness at excessive doses (U-curve reversal)
- Brain fog and grogginess the next day when overdosed
- Tolerance development with daily use (loss of effect after 1–2 weeks)
- Difficult dose-finding along the U-shaped curve
- Quality variability among research peptide vendors (purity unclear)
- Injection pain and local redness at the injection site
High non-responder rate (estimated 30–40%). Paradoxical insomnia and brain fog from overdosing along the U-shaped dose-response curve. Tolerance development with daily use without cycling. Quality variation between vendors (purity, peptide content). Immunogenicity risk from impure preparations and repeated injection.
Scientific Sources
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Monti JM et al. (1987). Int J Clin Pharmacol ResCPMID:3583493 - Delta-sleep-inducing peptide stimulates the release of Met-enkephalin from rat medullary synaptosomes
Nakamura A et al. (1991). Journal of NeurochemistryBPMID:1861139DOI - Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Frontiers Authors (2024). Frontiers in PharmacologyBDOI - Corticotropin-releasing hormone administration elicits aberrant delta sleep-inducing peptide responses in patients with major depression
Linkowski P et al. (1989). Journal of Clinical Endocrinology and MetabolismCPMID:2839244DOI - Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
MDPI Authors (2021). Molecules (MDPI)BLink - Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
Schneider-Helmert D et al. (1981). Int J Clin Pharmacol Ther ToxicolCPMID:6895513 - DSIP in the treatment of withdrawal syndromes from alcohol and opiates
Dick P et al. (1984). Eur NeurolCPMID:6548969DOI - Delta-sleep-inducing peptide stimulates the release of Met-enkephalin from rat medullary synaptosomes
Nakamura A et al. (1991). J NeurochemBPMID:1861139DOI - Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Frontiers Authors (2024). Frontiers in PharmacologyBDOI - Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor
Yehuda S et al. (1984). Neurosci LettBPMID:3029331 - Corticotropin-releasing hormone administration elicits aberrant delta sleep-inducing peptide responses in patients with major depression
Linkowski P et al. (1989). J Clin Endocrinol MetabCPMID:2839244DOI - Delta-sleep-inducing peptide (DSIP): a review
Graf MV, Kastin AJ (1984). BPMID:6145137 - DSIP in the treatment of withdrawal syndromes from alcohol and opiates
Dick P et al. (1984). European NeurologyCPMID:6548969DOI
Community Sources
Storage
Unopened
Store lyophilized powder at −20 °C in a freezer, protected from light. For short-term storage (a few weeks), 2–8 °C is sufficient. Shelf life under optimal conditions: several years.
Opened
After reconstitution with bacteriostatic water, store strictly at 2–8 °C (ideally 4 °C). Use within a maximum of 28–30 days. Never freeze reconstituted solution – ice crystals irreversibly destroy the peptide chain.
Notes
Protect from light, humidity and mechanical agitation. During reconstitution, let water run slowly down the vial wall – do not spray directly onto the powder. Do not shake the vial. Visible cloudiness or precipitation = discard. Avoid repeated freeze-thaw cycles of the lyophilisate.